How Striatal Cholinergic Interneurons Affect Nicotine Withdrawal
Author Information
Author(s): Kim Baeksun, Kim Han Ah, Woo Junsung, Lee Hyeon‐Jeong, Kim Tae Kyoo, Min Hophil, Lee C. Justin, Im Heh‐In
Primary Institution: Korea Institute of Science and Technology
Hypothesis
Striatal cholinergic interneurons play a critical role in the physical symptoms of nicotine withdrawal.
Conclusion
Inhibiting striatal cholinergic interneurons or using the drug procyclidine can reduce the physical signs of nicotine withdrawal.
Supporting Evidence
- Cholinergic interneurons are crucial for generating the physical signs of nicotine withdrawal.
- Procyclidine mimicked the therapeutic effects of inhibiting cholinergic interneurons.
- Inhibition of striatal cholinergic interneurons prevented the reduction in striatal dopamine release during nicotine withdrawal.
- Genetic inhibition of striatal cholinergic interneurons did not affect other nicotine-dependent behaviors.
Takeaway
When mice had their brain cells that help control movement turned off, they showed fewer signs of feeling sick from not having nicotine. A medicine called procyclidine helped too.
Methodology
The study used genetic inhibition of striatal cholinergic interneurons in mice and assessed their behavior during nicotine withdrawal.
Potential Biases
Potential bias due to the specific mouse model used and the lack of gender consideration.
Limitations
The study did not consider gender effects and used a specific mouse line that may not fully represent nicotine physiology.
Participant Demographics
Mice were used in the study, with no specific demographic details provided.
Statistical Information
P-Value
0.0021
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website